Literature DB >> 17881141

Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.

Masoom A Haider1, Peter Chung, Joan Sweet, Ants Toi, Kartik Jhaveri, Cynthia Ménard, Padraig Warde, John Trachtenberg, Gina Lockwood, Michael Milosevic.   

Abstract

PURPOSE: To compare the performance of T2-weighted (T2w) imaging and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) of the prostate gland in the localization of recurrent prostate cancer in patients with biochemical failure after external beam radiotherapy (EBRT). METHODS AND MATERIALS: T2-weighted imaging and DCE MRI were performed in 33 patients with suspected relapse after EBRT. Dynamic contrast-enhanced MRI was performed with a temporal resolution of 95 s. Voxels enhancing at 46 s after injection to a greater degree than the mean signal intensity of the prostate at 618 s were considered malignant. Results from MRI were correlated with biopsies from six regions in the peripheral zone (PZ) (base, mid, and apex). The percentage of biopsy core positive for malignancy from each region was correlated with the maximum diameter of the tumor on DCE MRI with a linear regression model.
RESULTS: On a sextant basis, DCE MRI had significantly better sensitivity (72% [21of 29] vs. 38% [11 of 29]), positive predictive value (46% [21 of 46] vs. 24% [11 of 45]) and negative predictive value (95% [144 of 152] vs. 88% [135 of 153] than T2w imaging. Specificities were high for both DCE MRI and T2w imaging (85% [144 of 169] vs. 80% [135 of 169]). There was a linear relationship between tumor diameters on DCE MRI and the percentage of cancer tissue in the corresponding biopsy core (r = 0.9, p < 0.001), with a slope of 1.2.
CONCLUSIONS: Dynamic contrast-enhanced MRI performs better than T2w imaging in the detection and localization of prostate cancer in the peripheral zone after EBRT. This may be helpful in the planning of salvage therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881141     DOI: 10.1016/j.ijrobp.2007.06.029

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  72 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

2.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Authors:  David M Schuster; Bital Savir-Baruch; Peter T Nieh; Viraj A Master; Raghuveer K Halkar; Peter J Rossi; Melinda M Lewis; Jonathon A Nye; Weiping Yu; F DuBois Bowman; Mark M Goodman
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

3.  Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer.

Authors:  Antonio C Westphalen; Galen D Reed; Phillip P Vinh; Christopher Sotto; Daniel B Vigneron; John Kurhanewicz
Journal:  J Magn Reson Imaging       Date:  2012-04-25       Impact factor: 4.813

4.  Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer.

Authors:  Ran Meng; Silvia D Chang; Edward C Jones; S Larry Goldenberg; Piotr Kozlowski
Journal:  Acad Radiol       Date:  2010-01-13       Impact factor: 3.173

5.  Treatment assessment of radiotherapy using MR functional quantitative imaging.

Authors:  Zheng Chang; Chunhao Wang
Journal:  World J Radiol       Date:  2015-01-28

6.  Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images.

Authors:  M Abd-Alazeez; N Ramachandran; N Dikaios; H U Ahmed; M Emberton; A Kirkham; M Arya; S Taylor; S Halligan; S Punwani
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-03       Impact factor: 5.554

Review 7.  MRI-only treatment planning: benefits and challenges.

Authors:  Amir M Owrangi; Peter B Greer; Carri K Glide-Hurst
Journal:  Phys Med Biol       Date:  2018-02-26       Impact factor: 3.609

Review 8.  Magnetic resonance image guided brachytherapy.

Authors:  Kari Tanderup; Akila N Viswanathan; Christian Kirisits; Steven J Frank
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

Review 9.  Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.

Authors:  Max Peters; Maaike R Moman; Henk G van der Poel; Henk Vergunst; Igle Jan de Jong; Peter L M Vijverberg; Jan J Battermann; Simon Horenblas; Marco van Vulpen
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

10.  Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Authors:  Olivio F Donati; Sung Il Jung; Hebert Alberto Vargas; David H Gultekin; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Michael J Zelefsky; Oguz Akin
Journal:  Radiology       Date:  2013-03-12       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.